Finerenone
I need to clarify an important issue: The evidence provided discusses finerenone (a nonsteroidal mineralocorticoid receptor antagonist), not "fenerenone." The FDA drug labels 111 appear to be for a topical analgesic product containing capsaicin, lidocaine, menthol, and methyl salicylate—completely unrelated to cardiovascular medicine. I will address finerenone based on the robust clinical evidence available.
Indications
Finerenone is indicated for patients with type 2 diabetes and chronic kidney disease (CKD) with albuminuria, and for heart failure with left ventricular ejection fraction (LVEF) ≥40% 23.
Specific Patient Populations:
For CKD with Type 2 Diabetes:
- eGFR ≥25 mL/min/1.73 m²
- Albuminuria (ACR ≥30 mg/g)
- Already on maximum tolerated RAS inhibitor (ACEi or ARB)
- Serum potassium ≤5.0 mmol/L 2
For Heart Failure (HFmrEF/HFpEF):
- LVEF ≥40%
- NYHA class II-IV symptoms
- Elevated natriuretic peptides
- On guideline-directed medical therapy 43
Dosing
Starting dose is determined by baseline eGFR 2:
- eGFR >60 mL/min/1.73 m²: Start 20 mg once daily
- eGFR 25-60 mL/min/1.73 m²: Start 10 mg once daily
Uptitration:
- After 4 weeks, if potassium <4.8 mmol/L and tolerating well, increase 10 mg dose to 20 mg daily
- Target maintenance dose: 20 mg once daily 2
Dose adjustments for hyperkalemia:
- Potassium >5.5 mmol/L: Withhold finerenone; restart at 10 mg daily when potassium ≤5.0 mmol/L
- Potassium 4.8-5.5 mmol/L: Continue current dose with close monitoring
- Can continue finerenone even if eGFR drops <25 mL/min/1.73 m² as long as potassium remains acceptable 2
Monitoring Parameters
Baseline Assessment:
- Serum potassium (must be ≤5.0 mmol/L to initiate)
- Serum creatinine and eGFR
- Confirm symptomatic heart failure diagnosis (exclude mimickers)
- Review drug interactions (especially strong CYP3A4 inhibitors)
Follow-up Monitoring:
- Check potassium and renal function at 4 weeks after initiation or any dose change 2
- Continue regular monitoring during treatment
- Reassess during acute illness or unstable renal function 5
- Monitor for signs of volume depletion or hypotension 64
Contraindications
Absolute contraindications:
- Baseline serum potassium >5.0 mmol/L (FDA label) or >4.8 mmol/L (trial criteria) 2
- eGFR <25 mL/min/1.73 m² at initiation 2
- Concomitant use of strong CYP3A4 inhibitors
- Pregnancy 1
Relative contraindications requiring caution:
- Concurrent use with other potassium-sparing agents
- Severe hepatic impairment
- Addison's disease
Adverse Effects
Most Common:
Hyperkalemia is the primary concern:
- Finerenone increases hyperkalemia risk 2-fold compared to placebo (RR 2.07) 6
- However, finerenone has lower hyperkalemia risk than spironolactone (RR 0.41) in HFrEF 6
- With protocol-directed monitoring and dose adjustment, clinical benefit is maintained even when potassium rises >5.5 mmol/L 4
Hypotension:
- 49% increased risk compared to placebo (RR 1.49) 6
- Monitor blood pressure, especially in volume-depleted patients
Worsening Renal Function:
- Paradoxically, finerenone actually improved renal function in switching studies, with decreased creatinine and increased eGFR 7
Overall Safety Profile:
- Fewer treatment-emergent adverse events than eplerenone (RR 0.93) 6
- Fewer serious adverse events than eplerenone (RR 0.74) 6
- Lower discontinuation rates than spironolactone in HFrEF 6
- No major cardiovascular events or severe adverse events in switching studies 7
Clinical Efficacy
Cardiovascular Outcomes:
- Reduces composite of cardiovascular death and total worsening HF events 3
- 17% reduction in HF hospitalization (HR 0.83) 8
- 9% reduction in all-cause mortality (HR 0.91) 3
- Cardiovascular death reduction not statistically significant as individual endpoint 5
Renal Outcomes:
- 20% reduction in composite kidney outcomes (HR 0.80) 3
- Decreased urinary albumin-to-creatinine ratio 7
Biomarker Improvements:
- Significant BNP reduction at 3 and 6 months 7
- Improved diastolic function 9
- Anti-inflammatory and antifibrotic effects 10
Integration with Other Therapies
Finerenone should complement, not replace:
- SGLT2 inhibitors (additive benefit demonstrated) 59
- ACEi or ARB (required background therapy)
- Beta-blockers
- Diuretics for decongestion
- Atrial fibrillation management
- Blood pressure control
- Exercise and nutrition 5
Key Clinical Pearls
- Finerenone is NOT indicated for hypertension alone—it is for cardiorenal protection in specific populations 5
- The drug works across the cardiovascular-kidney-metabolic syndrome spectrum 3
- Benefits appear consistent regardless of age, sex, baseline kidney function, or concurrent SGLT2 inhibitor use 9
- More selective and safer than steroidal MRAs (spironolactone/eplerenone), with fewer endocrine side effects and lower hyperkalemia risk 610